multiphasic moods and comprises six mood scales classified into one positive vigor and five negative tension-anxiety, depression-dejection, anger-hostility, fatigue, and confusion moods 17 . Most other tests only measure one aspect of mood, such as depression with the Self-rating Depression Scale and anxiety with the Manifest Anxiety Scale. POMS can be used to evaluate both patients and healthy people, and is standardized in various countries. Thus, POMS is considered suitable to multiphasically evaluate mood in healthy participants. Several intervention trials have evaluated the effect of DHA/EPA supplementation on mood in healthy adults 18 20 and elderly participants 21 by using POMS, although no study regarding ARA supplementation has been reported. In healthy adults, Fontani et al. evaluated the effect of LCPUFA supplementation 1.6 g/day EPA and 0.8 g/day DHA for 5 weeks on the mood in healthy adults 18, 19 . EPA/DHA supplementation led to an increased score for the positive mood vigor and decreased scores for the five negative moods tension-anxiety, depression-dejection, anger-hostility, fatigue, and confusion . In another study, supplementation with 1.7 g/day EPA and 0.3 g/day DHA for 4 weeks slightly improved fatigue 20 . Regarding healthy elderly participants, only one study has evaluated the effect of DHA/EPA 0.4 or 1.9 g/day supplementation, and no obvious effects of LCPUFA on mood were observed 21 . These studies suggest that LCPUFA supplementation improves the mood in young and middle-aged healthy people. However, the effects of LCPUFA on the mood in healthy elderly people remains unknown. Therefore, we hypothesized that LCPUFA supplementation improves mood in healthy elderly individuals. The objective of this study was to evaluate the effects of LCPUFA supplementation on mood in cognitively and emotionally normal elderly people. Previously, we conducted a randomized controlled trial RCT to evaluate the efficacy of LCPUFA 300 mg/day DHA, 100 mg/day EPA, and 120 mg/ day ARA on cognitive function in Japanese elderly men 22 .
In the present study, we examined the effect of this supplementation on POMS in elderly Japanese men by analyzing the secondary outcome from this previously performed RCT on cognitive function.
EXPERIMENTAL

Study design and participants
This study was performed by analyzing the secondary outcome in the previously performed randomized, doubleblind, placebo-controlled, parallel group intervention trial. This study was designed to evaluate the effects of LCPUFA supplementation on cognitive function in elderly Japanese men. The details of the participants and the study design, including inclusion and exclusion criteria for enrollment in this study, were described previously 22 . In brief, the participants were Japanese males aged 55-64 years without dementia or depression. Four hundred thirteen participants were screened, and 115 were randomly allocated to the placebo or LCPUFA group. Participants received capsules with purified olive oil placebo or LCPUFA-containing oil including DHA, EPA, and ARA for 4 weeks. The MiniMental State Examination and Beck Depression InventorySecond Edition were used for screening. Samples of blood and urine were obtained after an overnight fast. Physical and physiological parameters were measured, and the POMS was assessed at baseline and 4 weeks after the supplementation period. The fatty acid content in plasma phospholipids and dietary fatty acid intake was measured at baseline and 4 weeks after the supplementation period. The Ethics Committee on Human Experimentation of Suntory Holdings Ltd. approved the study protocol, which conformed to the principles set forth in the Declaration of Helsinki. Written informed consent was obtained from all participants before their entry to this study.
Randomization and allocation
As described previously 22 , the enrolled participants were assigned in a 1:1 ratio to one of the two masked supplements, placebo or LCPUFA, based on a random number table. The randomization codes for these participants and the codes for the masked supplements were held by two different people not involved in this study, and information regarding these assignments was masked to researchers until all data were collected and analyzed.
Experimental supplement
The experimental supplements in this study were purified olive oil and LCPUFA-containing oil, the fatty acid compositions of which were analyzed based on AOCS official method Ce 1b-89 35 and shown in Table 1 . In brief, LCP-UFA-containing oil or purified olive oil extracted from capsules was incubated with 0.5 M NaOH methanol solution at 100 . After cooling, BF 3 /methanol reagent was added to above solution and heated at 100 . Fatty acid methyl esters were extracted with n-hexane and analyzed using capillary gas-liquid chromatography. The LCPUFA group consumed 1,033 mg/day LCPUFA-containing oil in six soft gelatin capsules in which 300 mg DHA, 100 mg EPA, and 120 mg ARA were included as free fatty acid equivalents. The same amount of purified olive oil was administered in the placebo group. The participants were asked to take six capsules after their first meal for 4 weeks.
Outcome assessments
The primary outcomes of this RCT have been described previously 22 . In brief, the primary outcome of this study was cognitive processing speed evaluated by event-related potential P300. The secondary outcomes were mood assessed by POMS, LCPUFA DHA, EPA, and ARA content in plasma phospholipids, and dietary LCPUFA DHA, EPA, and ARA intake. A safety assessment was also performed, and it was previously reported that LCPUFA supplementation in the present study was considered safe under the conditions described here 22 .
Mood assessment with Pro le of Mood States
To report their mood over the preceding week, the participants were asked to fill out the Japanese edition of POMS, which comprises 65 questions 16, 17 . POMS consists of six mood scales classified into positive mood vigor and negative mood tension-anxiety, depression-dejection, anger-hostility, fatigue, and confusion scales. The 65 questions in POMS include 58 questions for mood scales vigor 8 , tension-anxiety 9 , depression-dejection 15 , angerhostility 12 , fatigue 7 , and confusion 7 and seven dummy questions. The participants selected from raw scores, which included five rating scores ranging from not at all 0 to extremely 4 . These raw scores were summed to generate six mood scales. To use parametric statistical analysis, the raw scores for each scale were converted to a standard score T-score from an age-and sexdependent conversion table 17 . The scaling of possible scores lowest to highest of the T-score is: vigor 26-79 ; tension-anxiety 31-85 ; depression-dejection 40-85 ; anger-hostility 37-85 ; fatigue 38-85 ; and confusion 31-85 . A score of 50 corresponds to the average score of standard data that consider age and sex.
Fatty acid analysis
Blood was centrifuged at 1,470 g for 10 min, and the plasma samples were stored at 80 prior to fatty acid analysis. Lipid extraction, purification, and fatty acid analysis were performed as described previously 22 . In brief, lipids in plasma were extracted and purified using the method of Folch et al. 31 . Each lipid fraction was separated using thin-layer chromatography, and fatty acids in phospholipids were transmethylated. Fatty acid methyl esters were extracted and analyzed using capillary gas-liquid chromatography Agilent 6890, Agilent Technologies, Santa Clara, CA, USA .
2.7 Dietary assessment and study diary As described previously 22 , the dietary habits of the participants during the preceding month were assessed using the brief self-administered diet history questionnaire BDHQ 32 . Dietary intake including DHA, EPA, and ARA was estimated using an ad hoc computer algorithm for the BDHQ based on the Standard Tables of Food Composition in Japan, 2010. The participants were asked to keep a record in the study diary throughout the study.
Statistical analysis
To assess the effect of LCPUFA supplementation on mood, the exclusion criteria for statistical analysis were: a change in dietary LCPUFA intake between baseline and 4 weeks after supplementation 3 times larger than the amount of LCPUFA supplementation ; an event affecting the mood, such as death of a relative, during the supplementation period. Data are shown as the mean standard error SE . Baseline data between the groups were compared with the unpaired t-test for quantitative variables or with the chi-square test or Mann-Whitney U test for qualitative variables. The change from baseline to 4 weeks after supplementation in each group was compared with the paired t-test. Comparisons of changes between groups were performed with the unpaired t-test. For all tests, twotailed p-values of less than 0.05 were considered to be statistically significant.
RESULTS
Participant ow and characteristics
The participant flow diagram is shown in Fig. 1 . A total of 413 participants were screened; 115 participants were enrolled and randomly allocated to the placebo n 58 or LCPUFA n 57 group. One participant in each group withdrew consent before the supplementation. One hundred thirteen participants placebo, n 57; LCPUFA, n 56 completed the 4-week supplementation period, and 100 participants placebo, n 49; LCPUFA, n 51 who were eligible for evaluation of mood were analyzed. Participants were excluded from the analysis for the following reasons: a change in dietary LCPUFA intake n 12 and experiencing an event that affected the mood n 1 . The baseline characteristics are shown in Table 2 . The placebo and LCPUFA groups were matched for age, height, body weight, body mass index, education, occupation, alcohol consumption, smoking status, LCPUFA DHA, EPA, and ARA composition in plasma phospholipids, and LCPUFA intake from daily diets.
Mood Pro le of Mood States
The six mood scales of POMS in both groups are shown in Fig. 2 . The vigor scores, reflecting positive mood, at baseline in the placebo and the LCPUFA groups were 49.9
1.5 and 48.7 1.3, respectively, with no significant difference between groups. The vigor score at 4 weeks in the LCPUFA group Fig. 2B was increased significantly by 1.8 p 0.009 vs. baseline , whereas that in the placebo group Fig. 2A was decreased by 0.5 compared with baseline, but not significantly. The change in vigor score after 4 weeks of supplementation Fig. 2C was significantly different between groups p 0.040 . Regarding the other five scores reflecting negative mood scales tension-anxiety, depression-dejection, anger-hostility, fatigue, and confusion , no significant differences were found between groups or between before and after supplementation. Table 3 shows the LCPUFA composition in plasma phospholipids. The DHA, EPA, and ARA content at baseline was not different between the two groups. DHA and ARA compositions in the LCPUFA group at 4 weeks were increased significantly by 0.8 p 0.001 vs. baseline and 0.7 p 0.001 vs. baseline , respectively. The DHA and ARA content in the placebo group remained unchanged during supplementation. Changes in the DHA and ARA content differed significantly between groups p 0.006 and 0.002, respectively . Regarding the EPA content in plasma, no significant differences were found between groups or between before and after supplementation. Table 4 shows fatty acid intake from daily diets. No significant differences were found in DHA, EPA, or ARA intake between groups or between before and after supplementation. In addition, changes in intake of these fatty acids did not differ between groups.
Fatty acid compositions in plasma phospholipids and fatty acid intake from daily diets
DISCUSSION
In the present study, we examined the effect of LCPUFA 300 mg/day DHA, 100 mg/day EPA, and 120 mg/day ARA on POMS in elderly Japanese men as the secondary outcome in a previously conducted RCT on cognitive function. The results showed that supplementation with LCPUFA improved positive mood vigor . This is the first report to suggest the efficacy of LCPUFA supplementation on mood in the elderly.
POMS comprises six mood scales classified into one positive vigor and five negative tension-anxiety, depression-dejection, anger-hostility, fatigue, and confusion moods. In the present study, the change in the vigor score for the LCPUFA group was significantly different from and 2.4 larger than that for the placebo group. The difference in vigor could be reliable because changes in all of the raw scores eight questions for vigor after 4-week supplementation in the LCPUFA group tended to be larger than those in the placebo group data not shown . The difference of 2.4 was comparable to differences due to the effects of known inventions, such as 2.4 g/day EPA/DHA supplementation 4.2 19 or forest therapy 4.4 3 in healthy adults.
These data suggest that the difference in vigor in the present study was psychologically meaningful, and that the efficacy of LCPUFA on vigor was observed regardless of age. On the other hand, the effects of LCPUFA on negative moods were not consistent with previous studies. Fontani et al. reported that 1.6 g/day EPA and 0.8 g/day DHA supplementation for 5 weeks not only increases vigor but also decreases tension-anxiety, depression-dejection, angerhostility, fatigue, and confusion in healthy adults 18, 19 . This inconsistency may be due to differences in the doses of LCPUFA or the characteristics of the study participants such as age and race. In addition, changes in the positive negative moods were not always linked in other intervention studies using foods 23, 24 . These data suggest that some interventions may independently affect positive and negative moods. In a previous study in the elderly, DHA/EPA 226 mg/day DHA and 176 mg/day EPA or 1093 mg/day DHA and 843 mg/day EPA supplementation for 26 weeks showed no obvious effects on mood 21 , although LCPUFA 300 mg/day DHA, 100 mg/day EPA, and 120 mg/day ARA supplementation for 4 weeks was effective on the positive mood under our study conditions. Making a conclusion regarding the efficacy of LCPUFA on mood in healthy elderly people is currently difficult. However, the various results may be due to differences among these studies in terms of the characteristics of subjects such as race, the combination of DHA, EPA, and ARA, or the supplementation period. Therefore, further studies are necessary to clarify the efficacy of LCPUFA on mood in healthy elderly people. Significant increases in DHA 0.8 and ARA 0.7 content in plasma phospholipids were observed in the LCPUFA group, although no significant changes were observed in the placebo group. The increase in DHA and ARA content in plasma phospholipids is considered to be within a reasonable range, because the increase in DHA content was 3.2 with 900 mg/day DHA supplementation 25 , and the increases in ARA content were 0.7 and 2.5 with 80 mg/day and 240 mg/day ARA supplementation, respectively 26, 27 . The EPA content in plasma phospholipids was likely not affected by the dose or the combination of LCPUFA 300 mg/day DHA, 100 mg/day EPA, and 120 mg/day ARA supplementation in this study condition.
On the other hand, we found no significant changes in Fig. 2 Scores of POMS in the placebo and LCPUFA g r o u p s a t b a s e l i n e a n d 4 w e e k s a f t e r supplementation. A Scores of POMS in the placebo group n 49 at baseline and 4 weeks after supplementation. We found no significant differences in the six moods between baseline and after supplementation paired t-test . Mean SE. B Scores of POMS in the LCPUFA group n 51 at baseline and 4 weeks after supplementation. ##p 0.01 vs. baseline paired t-test . Mean SE. C Changes in POMS after 4 weeks of supplementation in the placebo n 49 and LCPUFA n 51 groups. *p 0.05 vs. the placebo group unpaired t-test . Mean SE. D: depression-dejection, V: vigor, T-A: tensionanxiety, A-H: anger-hostility, F: fatigue, C: confusion. DHA, EPA, or ARA intake from daily diets between baseline and 4 weeks after supplementation in either group. These data suggest that the increases in plasma LCPUFA were due to LCPUFA supplementation.
Regarding the individual contribution of each LCPUFA component, EPA seems to affect mood in previous studies. Supplementation with LCPUFA using a higher dose of EPA than DHA improves mood in healthy young and middleaged people 18 20 . Moreover, EPA appears to ameliorate the symptoms of depression more than DHA 28 . In contrast, the present study suggests the possibility that DHA and ARA may be more effective than EPA on mood in the elderly, because only DHA and ARA but not EPA in plasma phospholipids were increased in this study. The individual contributions of DHA, EPA, and ARA on efficacy in the elderly are still unclear. An interesting question has arisen, and further studies using DHA, EPA, and/or ARA are expected to clarify the effects of individual LCPUFA. In previous studies, the effective dose of EPA/DHA for mood in healthy adults was more than 2 g/day 18 20 , which is higher than average dietary intake levels in various countries EPA, 0.05-0.4 g/day and DHA, 0.1-0.6 g/day 29 .
In the present study, the average amounts of DHA, EPA, and ARA intake from daily diets at baseline were 477 mg/ day, 282 mg/day, and 150 mg/day respectively, and were consistent with a previous report of Japanese elderly people DHA, 620 mg/day; EPA, 350 mg/day; and ARA, 170 mg/day 30 . The LCPUFA intake in this study can be considered typical in Japanese elderly people. We also confirmed that the dose of LCPUFA supplementation in the present study was in the range of that from daily diets. These data suggest that low doses of LCPUFA supplementation corresponding to dietary intake levels may have the potential to positively affect mood in the elderly. Our study has some limitations. First, the results of this study are based on the secondary outcome analysis of our previously performed RCT 22 . To clarify the efficacy, confirmatory studies are needed. Next, the sample size in this Mean SE. We found no significant difference between the groups in each fatty acid at baseline (unpaired t-test). # p < 0.05 vs. baseline (paired t-test). LCPUFA, long-chain polyunsaturated fatty acids; FA, fatty acid; LA, linoleic acid; ALA, a-linolenic acid; ARA, arachidonic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.
study was not large and further larger scale studies are needed to make a general conclusion. Then, the participants were only male. Regarding gender, moods measured by POMS raw scores are not affected by gender in Japanese elderly people 17 . In addition, blood DHA, EPA, and ARA levels in elderly men and women are similar 30 . These studies suggest that gender may have only a small effect in the present study, but further studies are necessary to clarify the effect of gender.
In conclusion, LCPUFA 300 mg/day DHA, 100 mg/day EPA, and 120 mg/day ARA supplementation improved the positive mood vigor in elderly Japanese men in these study conditions. This is the first report to suggest the efficacy of LCPUFA supplementation on mood in the elderly. Further studies are expected to clarify the efficacy.
